Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Pramipexole Combined with Levodopa Improves Motor Function but Reduces Dyskinesia in MPTP-Treated Common Marmosets

Identifieur interne : 001F23 ( Main/Exploration ); précédent : 001F22; suivant : 001F24

Pramipexole Combined with Levodopa Improves Motor Function but Reduces Dyskinesia in MPTP-Treated Common Marmosets

Auteurs : Kayhan A. Tayarani-Binazir [Royaume-Uni] ; Michael J. Jackson [Royaume-Uni] ; Sarah Rose [Royaume-Uni] ; C. Warren Olanow [États-Unis] ; Peter Jenner [Royaume-Uni]

Source :

RBID : Pascal:10-0161591

Descripteurs français

English descriptors

Abstract

Reduced expression of dyskinesia is observed in levodopa-primed MPTP-treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D-2/D-3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non-dyskinetic MPTP-treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04- 0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125-6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1-0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy.


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en" level="a">Pramipexole Combined with Levodopa Improves Motor Function but Reduces Dyskinesia in MPTP-Treated Common Marmosets</title>
<author>
<name sortKey="Tayarani Binazir, Kayhan A" sort="Tayarani Binazir, Kayhan A" uniqKey="Tayarani Binazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name>
<affiliation wicri:level="3">
<inist:fA14 i1="01">
<s1>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name>
<affiliation wicri:level="3">
<inist:fA14 i1="01">
<s1>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name>
<affiliation wicri:level="3">
<inist:fA14 i1="01">
<s1>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2">
<inist:fA14 i1="02">
<s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
<affiliation wicri:level="3">
<inist:fA14 i1="01">
<s1>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">INIST</idno>
<idno type="inist">10-0161591</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0161591 INIST</idno>
<idno type="RBID">Pascal:10-0161591</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000C20</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002099</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000898</idno>
<idno type="wicri:doubleKey">0885-3185:2010:Tayarani Binazir K:pramipexole:combined:with</idno>
<idno type="wicri:Area/Main/Merge">002485</idno>
<idno type="wicri:Area/Main/Curation">001F23</idno>
<idno type="wicri:Area/Main/Exploration">001F23</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a">Pramipexole Combined with Levodopa Improves Motor Function but Reduces Dyskinesia in MPTP-Treated Common Marmosets</title>
<author>
<name sortKey="Tayarani Binazir, Kayhan A" sort="Tayarani Binazir, Kayhan A" uniqKey="Tayarani Binazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name>
<affiliation wicri:level="3">
<inist:fA14 i1="01">
<s1>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name>
<affiliation wicri:level="3">
<inist:fA14 i1="01">
<s1>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name>
<affiliation wicri:level="3">
<inist:fA14 i1="01">
<s1>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
<affiliation wicri:level="2">
<inist:fA14 i1="02">
<s1>Department of Neurology, Mount Sinai School of Medicine</s1>
<s2>New York, New York</s2>
<s3>USA</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName>
<region type="state">État de New York</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
<affiliation wicri:level="3">
<inist:fA14 i1="01">
<s1>Neurodegenerative Diseases Research Centre, School of Health and Biomedical Sciences, King's College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<series>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt>
<title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Disability</term>
<term>Dyskinesia</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Pramipexole</term>
<term>Primates</term>
<term>Treatment</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Dyskinésie</term>
<term>Maladie de Parkinson</term>
<term>Pathologie du système nerveux</term>
<term>Pramipexole</term>
<term>Lévodopa</term>
<term>Traitement</term>
<term>Incapacité</term>
<term>Primates</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Reduced expression of dyskinesia is observed in levodopa-primed MPTP-treated common marmosets when dopamine agonists are used to replace levodopa. We now investigate whether a combination of the D-2/D-3 agonist pramipexole and levodopa also reduces dyskinesia intensity while maintaining the reversal of motor disability. Drug naïve, non-dyskinetic MPTP-treated common marmosets were treated daily for up to 62 days with levodopa (12.5 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) or pramipexole (0.04- 0.3 mg/kg BID) producing equivalent reversal of motor disability and increases in locomotor activity. Levodopa alone resulted in marked dyskinesia induction but little or no dyskinesia resulted from the administration of pramipexole. From day 36, some animals were treated with a combination of levodopa (3.125-6.25 mg/kg plus carbidopa 12.5 mg/kg p.o. BID) and pramipexole (0.1-0.2 mg/kg p.o. SID). This improved motor disability to a greater extent than occurred with levodopa alone. Importantly, while dyskinesia was greater than that produced by pramipexole alone, the combination resulted in less intense dyskinesia than produced by levodopa alone. These results suggest that pramipexole could be administered with a reduced dose of levodopa to minimize dyskinesia in Parkinson's disease while maintaining therapeutic efficacy.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region>
<li>Angleterre</li>
<li>Grand Londres</li>
<li>État de New York</li>
</region>
<settlement>
<li>Londres</li>
</settlement>
</list>
<tree>
<country name="Royaume-Uni">
<region name="Angleterre">
<name sortKey="Tayarani Binazir, Kayhan A" sort="Tayarani Binazir, Kayhan A" uniqKey="Tayarani Binazir K" first="Kayhan A." last="Tayarani-Binazir">Kayhan A. Tayarani-Binazir</name>
</region>
<name sortKey="Jackson, Michael J" sort="Jackson, Michael J" uniqKey="Jackson M" first="Michael J." last="Jackson">Michael J. Jackson</name>
<name sortKey="Jenner, Peter" sort="Jenner, Peter" uniqKey="Jenner P" first="Peter" last="Jenner">Peter Jenner</name>
<name sortKey="Rose, Sarah" sort="Rose, Sarah" uniqKey="Rose S" first="Sarah" last="Rose">Sarah Rose</name>
</country>
<country name="États-Unis">
<region name="État de New York">
<name sortKey="Olanow, C Warren" sort="Olanow, C Warren" uniqKey="Olanow C" first="C. Warren" last="Olanow">C. Warren Olanow</name>
</region>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F23 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001F23 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     Pascal:10-0161591
   |texte=   Pramipexole Combined with Levodopa Improves Motor Function but Reduces Dyskinesia in MPTP-Treated Common Marmosets
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024